All about the Deepbridge Life Sciences SEIS Fund

For over 40 years, the UK life sciences industry has been one of the most successful on a global basis. In 2012, the UK Government published the Strategy for UK Life Sciences, acknowledging the changing nature of the health life sciences sector, with a growing number of SMEs playing a leading role in driving growth.

The Deepbridge Life Sciences SEIS intends to participate in this changing business environment, securing compelling investment opportunities derived from a long-lasting legacy of scientific research and innovation in the United Kingdom.

The fund aims to invest in a diversified portfolio of early-stage life science companies that qualify fo the considerable income tax, capital gains tax, and inheritance tax benefits of the Seed Enterprise Investment Scheme.

The fund will invest in up to 10 seed-stage life sciences companies operating in the following areas:

• Biopharmaceuticals • Biotechnology • Medical Technology

These types of company may focus on any of the following:

• Anti-viral drug discovery and development • Antibiotic drug discovery and development • Neurodegenerative disease therapeutics • Cancer diagnostics and therapeutics • Autoimmune and other metabolic disorders therapies.

In addition to investment by Deepbridge, Deepbridge aim to help companies with non-dilutive matched funding from regional development funds, as well as research grant funding, both provided on an unsecured basis.

Deepbridge will add further value to Investee Companies by taking a seat on the Board of Directors and using an extensive industry network to access advice and commercial support to the business.

Summary

Fund Manager: Deepbridge Capital
Tax Efficiency: SEIS
Sector Focus: Technology
Stage Focus: Seed
Target Portfolio Size: 6-10 companies
Minimum Subscription: £10,000
Closing Date: Currently closed
Website: Learn more about Deepbridge Life Sciences SEIS Fund

Pros & Cons

Pros: Investors who come through advisors pay no fees so the full of their investment into the fund is deployed and thus is eligible for SEIS relief. Deepbridge Capital was founded in 2010 and is an established firm that runs multiple SEIS, EIS and other tax-efficient funds.

Cons: While no fees for investors is a good thing the fees to the companies mean they have less capital to operate the business and are required to pay the fund manager until there is an exit for the business.

Fees

Full initial fee: 2.5% direct, 0% advised
Annual management fee: nil
Administration fee nil
Performance fee: 20% of cash returned in excess of 150% of the funds invested

Investee company fees

Dealing fee: 0.65% on purchase of shares
Annual maintenance fee: 2% of the funds invested in the company
Annual custody: 0.5%

How does SyndicateRoom's Access EIS Fund compare?

By comparison, SyndicateRoom's Access EIS fund builds investors a large portfolio of 50+ companies across all sectors, co-investing with experienced angel investors who have an average IRR of 42%. Our model is based on our proprietary analysis of the UK startup market, which showed that on average, the market grows by 28% each year. With large portfolios, and a large network of angels providing access to the best deals, earlier, we aim to replicate that annual growth for our investors while mitigating risk. This data-driven approach aims to work around the limitations of a single fund manager attempting to pick winners.

Our minimum investment is £5,000.

Fund Manager: SyndicateRoom
Tax Efficiency: EIS
Sector Focus: Sector Agnostic
Stage Focus: Early-stage
Target Portfolio Size: 50+ companies
Minimum Subscription: £5,000
Closing Date: Evergreen
Website: Learn more about the Access EIS Fund
Please note: SyndicateRoom is not affiliated with Jenson Funding Partners. This page is for informational purposes only, and is the result of research conducted by SyndicateRoom. Whilst every effort has been taken to ensure accuracy at the time of publication this cannot be guaranteed and information is liable to change. Information displayed is neither a recommendation to invest or not, nor advice. With investments, your capital is at risk. SyndicateRoom is not responsible for the content of any external websites linked to from this page.

Are you the fund manager? Email tom@syndicateroom.com with any comments or amends.